\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationOnline
ProgrammesThe Digital Europe Programme 2023-2024 proposes a Coordination and Support action (CSA), to apply a cross-sector perspective to all existing sectorial Testing and Experimentation Facilities (TEFs).To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI.
This Coordination and Support action (CSA), driven by the TEFs needs, will support the sectorial TEFs to develop complementary cross-TEF activities in providing AI services from a cross-sector perspective and to maximise the overall impact of TEFs, and help the sectorial TEFs to better link with relevant EU projects, initiatives and stakeholders in the AI ecosystem of excellence. By boosting the reinforcing feedback loops, the CSA will also bolster the sectorial TEF’s and the ecosystem’s sustainability.
The responsible unit (DG Connect, Robotics and Artificial Intelligence Innovation and Excellence Unit) will hold an info session on 17th of May of 2023 from 9:00 to 10:30 AM (CET, Brussels time).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
